Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes.
Kelleher
A D
AD
Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK.
Booth
B L
BL
Sewell
A K
AK
Oxenius
A
A
Cerundolo
V
V
McMichael
A J
AJ
Phillips
R E
RE
Price
D A
DA
D000251:Adenosine Triphosphatases / Q000378:metabolism; D017951:Antigen Presentation / Q000502:physiology; D003546:Cysteine Endopeptidases / Q000187:drug effects*; D000939:Epitopes / Q000096:biosynthesis / Q000276:immunology; D005805:Genes, MHC Class I; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D009097:Multienzyme Complexes / Q000187:drug effects*; D010455:Peptides / Q000276:immunology / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex; D019438:Ritonavir / Q000627:therapeutic use*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000939:Epitopes; D017320:HIV Protease Inhibitors; D009097:Multienzyme Complexes; D010455:Peptides; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; D000251:Adenosine Triphosphatases; D019438:Ritonavir